
Loading, please wait...

Loading, please wait...

For patients with heart failure and left bundle-branch block (LBBB), achieving optimal cardiac resynchronization is critical for survival and quality of life. Traditional biventricular pacing (BiVP) has long been the gold standard, yet many patients do not respond to this therapy. Recent findings from the HeartSync-LBBP randomized clinical trial suggest that left bundle-branch pacing outcomes are superior, offering a more physiological alternative for conduction system restoration.
The HeartSync-LBBP trial enrolled 200 patients across multiple centers to compare the long-term clinical efficacy of Left Bundle-Branch Pacing (LBBP) against BiVP. After a median follow-up of 36 months, the results were definitive. The primary composite end point—which included time to death from any cause or heart failure hospitalization (HFH)—occurred in only 8% of the LBBP group. In contrast, 28% of the BiVP group reached this end point. This 74% relative risk reduction highlights the potential of LBBP to become the new primary strategy for cardiac resynchronization therapy (CRT).
Beyond survival and hospitalization, the trial evaluated the physiological impact on cardiac function. Patients receiving LBBP showed significantly higher super-response rates, defined as an absolute increase in left ventricular ejection fraction (LVEF) of 15% or more, or an improvement of LVEF to at least 50%. Specifically, 65% of the LBBP group achieved super-response compared to 44% in the BiVP group. Additionally, the success rate for lead implantation remained high in both groups, though LBBP demonstrated a slight edge at 98% compared to 94% for BiVP. These findings underscore how left bundle-branch pacing outcomes transcend basic pacing, providing robust mechanical and electrical synchronization.
The trial's data suggest that LBBP not only narrows the QRS duration more effectively than BiVP but also leads to more substantial reverse remodeling of the left ventricle. For clinicians managing chronic systolic heart failure, these long-term results provide the robust evidence needed to consider conduction system pacing as a first-line alternative to traditional epicardial pacing via the coronary sinus. Furthermore, the stable pacing thresholds and high success rates make LBBP a viable and potentially more effective solution for complex heart failure cases.
According to the HeartSync-LBBP trial, the primary advantage of LBBP is a significant reduction in the composite risk of all-cause mortality and heart failure hospitalizations, alongside better LVEF improvement compared to BiVP.
The HeartSync-LBBP trial reported high success rates for both procedures, with LBBP at 98% and BiVP at 94%. While LBBP requires specific lead placement techniques, it is highly feasible in experienced centers.
Heart failure patients with an LVEF of 35% or less and LBBB are the primary candidates who may benefit from the superior physiological synchronization offered by LBBP.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Chen X et al. Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial. JAMA Cardiol. 2026 Mar 11. doi: 10.1001/jamacardio.2026.0083. PMID: 41811342.
Vijayaraman P, et al. Conduction System Pacing for Cardiac Resynchronization: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023;82(11):1123-1141.
Lakshman H, et al. Clinical and Electrophysiological Outcomes of Left Bundle Area Pacing Compared to Biventricular Pacing: An Updated Meta-analysis. Innovations in CRM. 2024;15(5):5821-5830.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The HeartSync-LBBP trial demonstrates that LBBP significantly reduces mortality and heart failure hospitalizations compared to BiVP in LBBB patients....
7 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today